🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

186 results for “Air” Clear

  1. ACIDE FOLIQUE CCD 5 mg, comprimé, PLACEBO D'ASPIRINE PROTECT, ASPIRINE PROTECT 100 mg, comprimé gastro-résistant, PLACEBO D'ACIDE FOLIQUE

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  2. Actovegin

    Takeda Pharmaceuticals International AG

    Post-Stroke Cognitive Impairment (PSCI)

    phase 3 small molecule completed

    1 trial

  3. Balcinrenone+Dapagliflozin, Balcinrenone+Dapagliflozin, Forxiga, Balcinrenone+Dapagliflozin, Forxiga 10 mg film-coated tablets

    AstraZeneca AB

    Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death

    phase 3 small molecule active

    1 trial

  4. DEXAMETHASONE PHOSPHATE, Placebo of dexamethasone

    Pari Pharma GmbH

    respiratory distress due to upper airway obstruction in child

    phase 3 small molecule active

    1 trial

  5. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Ophthalmics Europe

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  6. Fluticasone propionate,Salbutamol sulfate, ProAir® RespiClick®, ProAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Pharma Mar S.A.

    Asthma

    phase 3 small molecule active

    1 trial

  7. Idursulfase (idursulfase-IT [HGT-2310])

    Takeda Pharmaceuticals International AG

    Hunter Syndrome and Cognitive Impairment

    phase 3 small molecule active

    1 trial

  8. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

  9. Lecanemab

    Eisai GmbH

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial

  10. Medical Air, KALINOX 50%/50%, gaz médicinal comprimé

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  11. Metalyse 5 000 units (25 mg) powder for solution for injection

    Pari Pharma GmbH

    Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

    phase 3 small molecule active

    1 trial

  12. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    Novo Nordisk A/S

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  13. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    Novo Nordisk A/S

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  14. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  15. OXYGENE MEDICINAL LIQUIDE AIR LIQUIDE SANTE FRANCE, gaz pour inhalation, pour évaporateur fixe

    Tour Hekla

    Hypoxemic acute respiratory failure

    phase 3 small molecule active

    1 trial

  16. Omalizumab (Xolair)

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Urticaria

    phase 3 small molecule completed

    1 trial

  17. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  18. Pioglitazone

    Takeda Pharmaceuticals International AG

    Mild Cognitive Impairment Due to Alzheimer's Disease

    phase 3 small molecule terminated

    2 trials

  19. Pioglitazone

    Takeda Pharmaceuticals International AG

    Impaired Glucose Tolerance

    phase 3 small molecule completed

    1 trial

  20. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Ophthalmics Europe

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  21. ProAir® Digihaler®, Placebo TEV-56248, Albuterol Sulfate HFA, ArmonAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Pharma Mar S.A.

    Asthma

    phase 3 small molecule active

    1 trial

  22. RIFADINE 300 mg, gélule, ANSATIPINE 150 mg, gélule

    Tour Hekla

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    phase 3 small molecule active

    1 trial

  23. Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  24. Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources